Comparison
Two forms of the same GHRH-analog idea: one with a drug-affinity complex for week-long action, one without.
The DAC version trades physiologic GH pulses for convenience; the no-DAC form (Mod GRF 1-29) is the short-acting backbone used in the classic human pharmacology work and in most community stacks.
The drug-affinity complex binds albumin and extends half-life to roughly a week. Community schedules reflect that split: about 2 mg once weekly for the DAC form versus around 100 mcg one to three times daily for the no-DAC form.
Both have early human pharmacology behind them: randomized studies of CJC-1295 with DAC in healthy adults showing sustained GH and IGF-1 elevation, and older GHRH-analog work for the no-DAC backbone. Neither has controlled outcome trials for recovery, body composition, or anti-aging.
Community stacks favor no-DAC paired with ipamorelin, arguing daily pulses are more physiologic than the DAC's sustained elevation. That is mechanistic reasoning, not a tested comparison, and both forms appear in FDA compounding discussions and on the WADA prohibited list.
| Dimension | CJC-1295 DAC | CJC-1295 no DAC |
|---|---|---|
| Overall evidence grade | C | E |
| Evidence label | Limited human evidence | Evidence unclear |
| Regulatory status | Investigational / not approved | Investigational / not approved |
| Editorial confidence | Moderate confidence | Low confidence |
| Efficacy | 2/5 limited | 0/5 not mapped |
| Safety | 2/5 limited | 1/5 limited |
| Regulatory risk | 5/5 very high | 5/5 very high |
| Product quality risk | 5/5 very high | 5/5 very high |
| Primary claim categories | Healthy-adult GH and IGF-1 pharmacology, DAC-specific identity, HIV visceral-obesity registry context, FDA compounding and product-quality risk, Eligibility and product-quality context | CJC-1295 no-DAC naming limits, Modified GRF alias disambiguation, FDA compounding and product-quality limits, Historical GHRH analog context |
CJC-1295 DAC has DAC-specific investigational context: healthy-adult endocrine pharmacology, terminated registry context, regulatory review, and product-quality risk, not body-composition, anti-aging, recovery, or stack claims.
CJC-1295 no DAC is an identity and non-interchangeability topic. FDA separates non-DAC and DAC CJC-1295 as different active moieties, and DAC human pharmacology and registry evidence does not carry over to no-DAC CJC-1295 or Modified GRF products.
doi:10.1210/jc.2005-1536 PMID:16352683 Accessed 2026-06-09.
Randomized placebo-controlled healthy-adult study reporting dose-dependent GH and IGF-1 increases after subcutaneous CJC-1295 with no serious adverse reactions in that study context.
doi:10.1210/jc.2006-1702 PMID:17018654 Accessed 2026-06-09.
Healthy-men study reporting increased trough and mean GH secretion and IGF-1 with preserved GH pulsatility one week after a single injection.
PubMed. Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men 1985.
doi:10.1016/0196-9781(85)90124-x PMID:2866496 Accessed 2026-06-09.
Older human GHRH(1-29)-NH2 and D-Ala2 analogue response source; used only as historical Modified GRF naming context, not as direct evidence for modern CJC-1295 no-DAC products.
FDA. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting 2024.
Accessed 2026-06-09.
FDA briefing distinguishes DAC and non-DAC CJC-1295 forms as separate active moieties, states none of the reviewed substances are components of FDA-approved drugs, and summarizes characterization and safety concerns.
WADA. The 2026 Prohibited List: growth hormone releasing factors 2026.
Accessed 2026-06-09.
WADA lists CJC-1295 under prohibited growth hormone releasing factors and analogues in section S2.